# Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

Source: https://onco.cc/trials/nct05552755/  
OnCo record `nct05552755` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of REC-4881 run by Recursion Pharmaceuticals Inc., now recruiting.

## Summary

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) is a phase 1/2 interventional study registered as NCT05552755 by Recursion Pharmaceuticals Inc., with 67 participants planned, started 2023-07-10. Conditions recorded: Familial Adenomatous Polyposis. Interventions recorded: REC-4881 and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05552755
- Phase: 1/2
- Setting: A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)
- Sponsor: Recursion Pharmaceuticals Inc.
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT05552755: https://clinicaltrials.gov/study/NCT05552755

## Connected records

- cancers: [Familial adenomatous polyposis-associated colorectal cancer](https://onco.cc/cancers/fap-associated-colorectal-cancer/)
- drugs: [REC-4881](https://onco.cc/drugs/rec-4881/)
- companies: [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/)

---
JSON: https://onco.cc/api/v1/entities/nct05552755.json